MD20140104A2 - Polipeptide care se leagă de CX3CR1 - Google Patents

Polipeptide care se leagă de CX3CR1

Info

Publication number
MD20140104A2
MD20140104A2 MDA20140104A MD20140104A MD20140104A2 MD 20140104 A2 MD20140104 A2 MD 20140104A2 MD A20140104 A MDA20140104 A MD A20140104A MD 20140104 A MD20140104 A MD 20140104A MD 20140104 A2 MD20140104 A2 MD 20140104A2
Authority
MD
Moldova
Prior art keywords
polypeptides
cx3cr1
binding polypeptides
compositions
relates
Prior art date
Application number
MDA20140104A
Other languages
English (en)
Russian (ru)
Other versions
MD4548B1 (ro
MD4548C1 (ro
Inventor
Sanjaya Singh
Alisa K. Waterman
Erik Depla
Toon Laeremans
Hoorick Diane Van
Cedric Jozef Nèotère VERVERKEN
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47884535&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD20140104(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of MD20140104A2 publication Critical patent/MD20140104A2/ro
Publication of MD4548B1 publication Critical patent/MD4548B1/ro
Publication of MD4548C1 publication Critical patent/MD4548C1/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

Invenţia se referă la imunologie, în special la polipeptide care se leagă de CX3CR1, şi anume la polipeptide care cuprind domenii imunoglobulinice specifice.Invenţia se referă, de asemenea, la acizi nucleici care codifică astfel de polipeptide, la procedee de obţinere a unor astfel de polipeptide, la celule-gazdă care expresează sau sunt capabile să expreseze astfel de polipeptide, la compoziţii care conţin astfel de polipeptide şi la utilizări ale unor astfel de polipeptide sau ale acestor compoziţii în scopuri profilactice, terapeutice şi diagnostice.
MDA20140104A 2012-02-27 2013-02-25 Polipeptide care se leagă de CX3CR1 MD4548C1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261603622P 2012-02-27 2012-02-27
PCT/US2013/027580 WO2013130381A1 (en) 2012-02-27 2013-02-25 Cx3cr1-binding polypeptides

Publications (3)

Publication Number Publication Date
MD20140104A2 true MD20140104A2 (ro) 2015-02-28
MD4548B1 MD4548B1 (ro) 2018-01-31
MD4548C1 MD4548C1 (ro) 2018-08-31

Family

ID=47884535

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20140104A MD4548C1 (ro) 2012-02-27 2013-02-25 Polipeptide care se leagă de CX3CR1

Country Status (27)

Country Link
US (6) US9035029B2 (ro)
EP (2) EP4050027A3 (ro)
JP (1) JP6101715B2 (ro)
KR (1) KR102008136B1 (ro)
CN (3) CN104245735B (ro)
AP (1) AP2014007791A0 (ro)
AR (1) AR090158A1 (ro)
AU (1) AU2013226340B2 (ro)
CA (1) CA2862182A1 (ro)
CL (1) CL2014002072A1 (ro)
EA (1) EA028183B1 (ro)
EC (1) ECSP14020402A (ro)
GE (1) GEP201706773B (ro)
HK (1) HK1205154A1 (ro)
IL (2) IL291571B1 (ro)
IN (1) IN2014DN05756A (ro)
MD (1) MD4548C1 (ro)
MX (1) MX349192B (ro)
NZ (1) NZ627260A (ro)
PE (1) PE20141859A1 (ro)
PH (1) PH12014501912A1 (ro)
SG (1) SG11201405283SA (ro)
TN (1) TN2014000360A1 (ro)
TW (1) TWI598361B (ro)
UA (1) UA115781C2 (ro)
UY (1) UY34644A (ro)
WO (1) WO2013130381A1 (ro)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
MX349192B (es) 2012-02-27 2017-07-18 Boehringer Ingelheim Int Polipeptidos de union a cx3cr1.
US9637542B2 (en) * 2013-08-21 2017-05-02 Boehringer Ingelheim International Gmbh CX3CR1-targeting imaging agents and their use in the diagnosis and treatment of disease
RU2609627C2 (ru) * 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
CA2992298A1 (en) 2015-07-23 2017-01-26 Inhibrx Lp Multivalent and multispecific gitr-binding fusion proteins
EP3402507A4 (en) 2016-01-11 2019-08-07 Inhibrx, Inc. MULTIVALENT AND MULTISPECIFIC OX40-BINDING FUSION PROTEINS
TW201808990A (zh) * 2016-03-08 2018-03-16 馬弗瑞克療法公司 可誘導性結合蛋白和使用方法
US20200071408A1 (en) * 2016-11-29 2020-03-05 National Center Of Neurology And Psychiatry Prophylactic agent, onset-suppressing agent or therapeutic agent for progressive immune demyelinating diseases
US20190367623A1 (en) * 2017-01-17 2019-12-05 Yeda Research And Development Co. Ltd. Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells
AU2018328291B2 (en) 2017-09-08 2022-10-27 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
MX2021001703A (es) 2018-08-13 2021-04-19 Inhibrx Inc Polipeptidos de union a ox40 y sus usos.
CN114390938A (zh) 2019-03-05 2022-04-22 武田药品工业有限公司 受约束的条件性活化的结合蛋白
CN110675421B (zh) * 2019-08-30 2022-03-15 电子科技大学 基于少量标注框的深度图像协同分割方法
WO2022165434A2 (en) * 2021-02-01 2022-08-04 The General Hospital Corporation Fc-enhanced antibodies for prevention and treatment of ebola virus infection
US20240117038A1 (en) 2022-07-18 2024-04-11 Ablynx N.V. Cx3cr1-binding compounds, methods and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1087013T3 (da) 1992-08-21 2009-05-11 Univ Bruxelles Immunoglobuliner uden lette kæder
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
WO2001060406A1 (en) * 2000-02-18 2001-08-23 Millennium Pharmaceuticals, Inc. Therapeutic methods that target fractalkine or cx3cr1
CA2405709A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US20020192212A1 (en) * 2001-03-19 2002-12-19 Toshio Imai Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine
EP1399484B1 (en) 2001-06-28 2010-08-11 Domantis Limited Dual-specific ligand and its use
JP4123856B2 (ja) 2001-07-31 2008-07-23 日油株式会社 生体関連物質の修飾剤およびポリオキシアルキレン誘導体の製造方法
US20050069962A1 (en) 2001-10-12 2005-03-31 Archer Robert M Antibody complexes and methods for immunolabeling
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
CA2487438A1 (en) 2002-06-10 2003-12-18 Metabolex, Inc. Methods of treating and diagnosing diabetes with cx3cr1 modulators
EP2267032A3 (en) 2002-11-08 2011-11-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
KR101025143B1 (ko) 2002-12-31 2011-04-01 넥타르 테라퓨틱스 가수분해상으로 안정한 말레이미드－종결 중합체
PL1639011T3 (pl) 2003-06-30 2009-05-29 Domantis Ltd Pegilowane przeciwciała jednodomenowe (dAb)
WO2005103684A2 (en) 2004-04-20 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1)
AU2005293752A1 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as Alzheimer's disease
EP1806145B1 (en) 2004-10-29 2017-08-16 Eisai R&D Management Co., Ltd. Remedy for inflammatory diseases
EP1888640B1 (en) 2005-05-18 2012-03-14 Ablynx N.V. Improved nanobodies against tumor necrosis factor-alpha
US8642330B2 (en) 2005-08-08 2014-02-04 Onconon, Llc Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
AU2006283532B2 (en) * 2005-08-19 2012-04-26 Abbvie Inc. Dual variable domain immunoglobin and uses thereof
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
JP2010502208A (ja) * 2006-09-08 2010-01-28 アブリンクス エン．ヴェー． 半減期の長い血清アルブミン結合タンパク質
JP2010511397A (ja) 2006-12-05 2010-04-15 アブリンクス エン．ヴェー． 血清タンパク質と結合可能なペプチド
US20110091462A1 (en) 2008-03-05 2011-04-21 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making and uses thereof
AU2009237662A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
DK2285408T3 (en) 2008-06-05 2019-02-04 Ablynx Nv AMINO ACID SEQUENCES AGAINST COATING PROTEINS IN A VIRUS AND POLYPEPTIDES INCLUDING THESE FOR TREATMENT OF VIRUSAL DISEASES
WO2010070394A1 (en) 2008-12-17 2010-06-24 Universite Pierre Et Marie Curie-Paris Vi Modulators of the cx3cr1 receptor and therapeutic uses thereof
WO2011042398A1 (en) * 2009-10-09 2011-04-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
WO2011044377A2 (en) 2009-10-09 2011-04-14 Cell Point, Llc Chelator-targeting ligand conjugates for cardiovascular imaging
WO2012078633A2 (en) * 2010-12-07 2012-06-14 Philadelphia Health And Education Corporation, D/B/A Drexel University College Of Medicene Methods of inhibiting metastasis from cancer
MX349192B (es) 2012-02-27 2017-07-18 Boehringer Ingelheim Int Polipeptidos de union a cx3cr1.
US9637542B2 (en) 2013-08-21 2017-05-02 Boehringer Ingelheim International Gmbh CX3CR1-targeting imaging agents and their use in the diagnosis and treatment of disease

Also Published As

Publication number Publication date
CN104245735B (zh) 2018-02-23
MX2014009864A (es) 2014-10-24
CN104245735A (zh) 2014-12-24
CL2014002072A1 (es) 2015-01-23
JP6101715B2 (ja) 2017-03-22
US9458235B2 (en) 2016-10-04
EP2820046B1 (en) 2022-06-15
HK1205154A1 (en) 2015-12-11
PH12014501912A1 (en) 2014-11-24
CN108610421A (zh) 2018-10-02
SG11201405283SA (en) 2014-10-30
US20190322753A1 (en) 2019-10-24
US9783612B2 (en) 2017-10-10
CN115925938A (zh) 2023-04-07
AU2013226340A1 (en) 2014-07-31
MD4548B1 (ro) 2018-01-31
UA115781C2 (uk) 2017-12-26
US20150239971A1 (en) 2015-08-27
US10385134B2 (en) 2019-08-20
US20160355595A1 (en) 2016-12-08
TN2014000360A1 (en) 2015-12-21
KR20140130685A (ko) 2014-11-11
BR112014021080A2 (pt) 2017-07-04
EA028183B1 (ru) 2017-10-31
EP2820046A1 (en) 2015-01-07
IL234018B2 (en) 2023-05-01
GEP201706773B (en) 2017-11-27
AR090158A1 (es) 2014-10-22
PE20141859A1 (es) 2014-12-17
US20130224224A1 (en) 2013-08-29
CN108610421B (zh) 2022-08-19
AU2013226340B2 (en) 2017-06-22
US20180030141A1 (en) 2018-02-01
AP2014007791A0 (en) 2014-07-31
IL291571B1 (en) 2024-04-01
CA2862182A1 (en) 2013-09-06
KR102008136B1 (ko) 2019-08-08
EP4050027A3 (en) 2022-11-30
IN2014DN05756A (ro) 2015-04-10
ECSP14020402A (es) 2015-11-30
WO2013130381A1 (en) 2013-09-06
EA201400964A1 (ru) 2015-02-27
IL291571A (en) 2022-05-01
UY34644A (es) 2013-09-02
US20230046772A1 (en) 2023-02-16
US9035029B2 (en) 2015-05-19
US20240026013A2 (en) 2024-01-25
MD4548C1 (ro) 2018-08-31
IL234018B1 (en) 2023-01-01
TWI598361B (zh) 2017-09-11
NZ627260A (en) 2015-10-30
TW201348256A (zh) 2013-12-01
JP2015509368A (ja) 2015-03-30
US11384151B2 (en) 2022-07-12
IL234018A0 (en) 2014-09-30
MX349192B (es) 2017-07-18
EP4050027A2 (en) 2022-08-31

Similar Documents

Publication Publication Date Title
MD20140104A2 (ro) Polipeptide care se leagă de CX3CR1
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
TN2012000167A1 (en) Human il-23 antigen binding proteins
WO2014200910A3 (en) Bioinformatic processes for determination of peptide binding
MY162737A (en) 4-1bb binding molecules
MX371018B (es) Polipéptidos que tienen actividad de transgalactosilación.
PH12014502179B1 (en) Ang2-binding molecules
PH12016500275B1 (en) Antibodies
IN2014MN01562A (ro)
MX2015000754A (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
IN2013MN01394A (ro)
PH12018501114A1 (en) Polypeptides inhibiting cd40l
MX2019014504A (es) Inmunoglobulinas de union a agrecano.
MX2015012281A (es) Proteinas de union a tnf mejoradas.
MX2015014198A (es) Anticuerpos cuyo objetivo es m-csf.
WO2011085134A3 (en) Methods and compositions for the diagnosis, prognosis and treatment of cancer

Legal Events

Date Code Title Description
FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees